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Implantable Intrathecal Pumps for Chronic Pain: Highlights and Updates
Management of chronic pain by intrathecal delivery is gaining increas-
ing use. The aim of this article is to review the literature pertinent to 
implantable devices used for treatment of chronic pain, and to high-
light what is known. Articles were obtained from Medline database 
and reviewed. Practical patient selection criteria, trial management, 
and surgical technique are described. Expert consensus guidelines for 
intrathecal medication use are also reviewed. Finally, an exhaustive de-
scription of known complications and future implications is discussed. 
We concluded that intrathecal pump seems to be overused, while there 
is still weak evidence to support its outcome. It is also recommended 
that future research focus on the outcome, measured by functional pa-
rameters rather than commonly used pain scores.
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Review
Pain is one of the most common reasons patients visit their 
doctors (1). If pain persists it not only can cause physical dis-
ability, but also place emotional, economic, psychological 
strain on patients and their families. Chronic pain is exceed-
ingly prevalent. A variety of international studies have esti-
mated that between 10.1-55.2% of population are afflicted 
with pain (2). In the United States, it appears that 20 to 30% 
of the general population experience chronic or recurring pain 
(3). Approximately, 2/3 of these people have had pain for 
more than 5 years (4). These findings are consistent with the 
experience of other western European countries, such as Swe-
den and Denmark (3). In addition, pain is the most common 
symptom of patients presenting for palliative care and is pres-
ent in 67% of patients with metastatic cancer (5).
Pain puts a considerable economic strain on the frame-
work of society through lost productivity, disability, and 
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health care utilization. The cost of chronic pain 
has been estimated to be as high as $100 billion 
a year in the United States. In a recent European 
study on individuals suffering from neuropathic 
pain, 76% visited their physician at least once in 
the past month. Employment status was affect-
ed in 43% of patients; those working missed an 
average (±standard deviation) of 5.5 ± 9.8 work-
days during the past month (6). A study done 
in 2000 showed that 36 million workers missed 
work because of pain and that 83 million felt 
their pain interfered with participation in dai-
ly activities (4). These figures serve to clarify the 
need for effective long-term treatment modali-
ties for chronic pain.
Intrathecal analgesia
Intrathecal analgesia has a long history marked 
by advancements in technique and discoveries 
of new indications. The beginnings of spinal an-
algesia are set in the late 19th century, soon after 
the discovery of cocaine as a local anesthetic. In 
1898, August Bier produced the first document-
ed spinal analgesia by injecting cocaine into the 
intrathecal space of himself, his assistant, and 6 
patients undergoing operations on the lower part 
of the body (2,7). The potent anesthetic results 
were published in a hallmark paper that stirred 
immense interest and research in this treatment 
modality.
Among the first to use opioids for intrathe-
cal analgesia was Rudolph Matas, who in 1900 
discovered that mixing morphine with cocaine 
mitigated the adverse symptoms associated with 
intrathecal cocaine (8). His report was closely 
followed by that of the Japanese anesthesiologist 
Otojiro Kitagawa, who in 1901 published the 
use of intrathecal morphine in the treatment of 
vertebral inflammation (9).
The scientific study of spinal analgesia be-
gan soon after its discovery, but not until the dis-
covery of opiate receptors in the spinal cord, be-
ginning in 1973, was there a scientific rationale 
for intraspinal delivery of opioid drugs (10-12). 
Fields and Basbaum described the descending 
pain inhibition system in the substantia gelati-
nosa (13). This discovery laid the groundwork 
for the findings of J. Wang, who in 1979 report-
ed the successful use of intrathecal morphine for 
treatment of intractable cancer pain (14). The 
report by Wang sparked increased utilization of 
spinal opioids.
The first uses of continuous spinal analgesia 
were demonstrated in the 1940s, providing the 
avenue for future long-term pain management 
with spinal opioids. It was introduced clinically 
in 1979 for obstetric analgesia (15).
The first clinical use of an implantable intra-
thecal opioid delivery device was demonstrated 
in 1981 for use in chronic pain of malignancy 
(8). The efficacy and safety of this modality was 
supported by a succession of studies, establishing 
it an alternative therapy for chronic pain states 
(16-20). The use of opioids in implantable drug 
delivery systems for chronic non-malignant pain 
is a more recent application. Although its effica-
cy has been repeatedly demonstrated, it remains 
controversial amidst fears of tolerance and drug 
addiction by many lay persons, government reg-
ulators, and even some health care professionals. 
While morphine, because of its history, duration 
of action, and ease of use, remains the gold stan-
dard of intraspinal analgesia, other agents were 
added to the repertoire of intraspinal therapy 
during the last twenty years. Alternative opioids 
such as hydromorphone, alpha adrenergic agents, 
and baclofen for neuropathic pain are currently 
being used.
Patient selection
Patients needing intrathecal drug delivery can be 
divided into 2 broad categories. The first catego-
ry includes patients suffering from terminal ill-
nesses such as cancer. These individuals general-
ly respond well to intrathecal opioids if they have 
been successfully managed on oral opioids first. 
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Invasive therapy should be considered if they 
have responded well to opioids, but have devel-
oped increasing pain and intractable side effects 
despite rotating oral opioids. However, if pa-
tients are terminal and their life expectancy is less 
than six months, one has to weigh the benefits vs 
the risks of such a venture knowing that it some 
times takes to stabilize patients on a given dosing 
pattern. This type of therapy is generally recom-
mended for individuals with a life expectancy of 
greater than six months (21). It is important to 
rule out the presence of occult pathology in the 
spinal canal and any obstructive metastasis in the 
spinal column that could present a challenge dur-
ing insertion of the catheter.
The second category of patients is those with 
chronic non-malignant pain, for example, failed 
low back surgery syndrome. The use of intrathe-
cal drug delivery systems in chronic non-ma-
lignant pain is more controversial. One has to 
recognize that chronic non-malignant pain is 
complicated by physical, psychological, and be-
havioral factors. To be successful, a treatment 
must include a multidimensional approach that 
takes into account each of the elements of the 
biopsychosocial model. Clearly, treatment for 
chronic pain should consider conservative ap-
proaches before more invasive treatments are 
considered. These approaches include but are not 
limited to physical therapy and rehabilitation, 
psychological and behavioral intervention such 
as self-relaxation cognitive and behavioral thera-
pies (eg, biofeedback), pharmacotherapy, mini-
mally invasive interventions (such as epidural 
and transforaminal injections), and alternative 
therapies such as acupuncture.
Intrathecal drug delivery systems are implant-
ed for chronic pain when conservative therapies 
have failed, surgery is ruled out, no active or un-
treated addiction exists, psychological testing in-
dicates appropriateness for implantable therapy, 
medical contraindications have been eliminated 
(coagulopathies, infections), and a successful in-
trathecal drug trial has been completed (22).
Intrathecal pumps
Intrathecal pumps deliver small doses of med-
ication directly to the spinal fluid. It consists of 
a small battery-powered, programmable pump 
(Figure 1) that is implanted under the subcuta-
neous tissue of the abdomen and connected to a 
small catheter tunneled to the site of spinal entry 
(Figure 2). Sophisticated drug dose regimens can 
be instituted. Implanted pumps need to be re-
filled every 1 to 3 months. There is no evidence 
showing whether it is more clinically effective to 
use bolus or continuous dosing.
Figure 1. Intrathecal pump.
Figure 2. Intrathecal catheter.
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Trial
It is the recommendation of the authors that no 
intrathecal device should be implanted for pain 
management of chronic intractable pain without 
first performing a trial. The properly performed 
trial phase is of outmost importance. This phase 
determines whether a patient will benefit from 
an implant.
During the trial, the planned drug is infused 
through an indwelling catheter that could be 
placed intrathecally or epidurally. The advantage 
of intrathecal placement is that it is more physi-
ologic and mimics what the patient will eventu-
ally receive. It is advised that an infusion is done 
and that the tip of the catheter be placed at or 
close to the dermatomal level transmitting the 
nociceptive impulse. The advantage of the epi-
dural trial is avoiding intrathecal entry. It also 
allows a very specific response when the cath-
eter tip is placed close to the dermatome and a 
small volume of infusate is used. However, one 
is to expect more systemic side-effect. Start with 
a dose of hydromorphone of 0.3mg/d slowly ti-
trating to effect. Alternatively, morphine sulfate 
could be imitated at 0.2 mg/d with titration to 
approximately 2 mg/d. The trial is done for two 
to three days. Results are evaluated depending 
on patient’s and physician’s expectations. How-
ever, it must be said that a mild improvement in 
somebody’s symptoms should not be interpreted 
as a positive trial. Typically, one expects at least 
a 50% improvement in pain score and improve-
ment in function for the trial to be considered 
successful. It is not known at what dose the trial 
should be considered a failure. It depends on the 
dose of opioid the patient was taking prior to the 
trial. But generally, the above dose range reflects 
the common practice. The lack of objective inter-
pretation of trials has lead to unnecessary place-
ment of these devices which in turn lead to a low 
success rate. Placebo trial use is controversial and 
due to ethical issues is not recommended by the 
authors.
Surgical technique
The placement of an implantable intrathecal 
pump consists of the catheter placement fol-
lowed by implantation of the pump. The patient 
is placed in a lateral decubitus position, prepped, 
and draped in sterile fashion. Antibiotic prophy-
laxis is given 30 minutes prior to incision and an-
esthesia is induced. A posterior midline incision 
approximately 2-3 inches long is made from the 
skin to the supraspinous fascia at approximate-
ly L2-3 or 3-4. A 16g Touhy spinal needle is ad-
vanced through the incision into the epidur-
al space. Meticulous attention to hemostasis is 
needed using electrocautery. The wound may be 
rinsed with antibiotic irrigation to reduce the 
risk of infection. A shallow angled paramedian 
approach with the Touhy needle allows easy ros-
tral advancement of the catheter into the intra-
thecal space. To prevent catheter kinks, it is im-
portant that the needle enter the supraspinous 
fascia at the rostral end of the incision to ensure 
that the catheter has room caudally to gently exit 
and connect to the pump catheter. Some sur-
geons place a purse-string 2-0 silk suture around 
the Touhy needle before removing the needle to 
prevent cerebral spinal fluid (CSF) from entering 
the subcutaneous tissue creating a hygroma. Po-
sitioning of catheter is checked with fluoroscopy 
(Figure 3). Excessive CSF leaking may require a 
Figure 3. Radiographic catheter placement.
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re-operation to correct the leak. After removing 
the needle, the catheter is anchored to the supra-
spinous fascia using a silastic anchor provided by 
the manufacturer. The anchor is placed around 
and over the catheter and sutured with interrupt-
ed 2-0 or 3-0 silk sutures. It is possible to punc-
ture or occlude the catheter when suturing it. 
Therefore, before proceeding the end of the cath-
eter should be checked for free flowing CSF and 
then clamped to prevent excessive leakage.
Once the catheter is in place, the pump must 
be prepared for implantation. Careful review of 
the manufacturer’s recommendations for pump 
preparation is essential.
After the pump is prepared, an incision for 
the pump pocket is made in the right or left low-
er quadrant of the abdomen at or about the um-
bilical level. The pump should be placed below 
the belt line, but not too close to the anterior rib 
or iliac crest as it may lead to prolonged discom-
fort. Because of refilling requirements, it is im-
portant not to place the pump too deep. In an 
obese patient the pump should be placed at the 
mid-fat plane of the lower quadrant of the abdo-
men. If the patient is thin, then the pump may 
be placed at the rectus fascia. The incision for the 
pump pocket should be made just large enough 
to accommodate the pump. After creating the 
pump pocket, tunneling from the pump pocket 
to the back wound should be done with the tun-
neling device. It is vital that the tip of the tun-
neling device remains subcutaneous to prevent 
entering the peritoneal cavity or pleural cavity. 
Gentle subcutaneous guidance of the tip with a 
gently applied pressure on the skin overlying the 
tip will usually ensure safe tunneling. Once the 
tunnel has been created, the catheter can now be 
pulled through the tunnel to the pump site. The 
catheter should be measured, trimmed if needed, 
and connected to the pump. Prior to connecting 
the catheter, it is important to once again veri-
fy the free flow of CSF from the catheter. The 
pump is now placed into the pocket reservoir 
side up. Any excess catheter should be placed be-
hind the pump to prevent damage to the cathe-
ter during refilling. The pump should be secured 
to the pocket by suturing to the abdominal fascia 
under the pump pocket. If there are no loops on 
the pump, then a Dacron pouch should be care-
fully placed over the pump and serve as an an-
choring device. Over time, fibroblasts invade the 
Dacron pouch forming a tight fibrous capsule 
around the pump. Before closing the wounds, it 
is important to establish adequate hemostasis to 
prevent the risk of post-operative infections. The 
wounds should be closed in a two layer closure 
according to the preference of the surgeon.
After the wounds are closed and the patient 
is taken to the recovery area, the pump can be 
programmed to deliver the prescribed amount of 
medication. Because the pump tubing and cath-
eter are not filled with medication, a bridge bo-
lus must be performed in order to clear the dead 
space and deliver the prescribed medication dose.
Medications
Medications used in implantable drug delivery 
systems include opioids, local anesthetics, adren-
ergic agonists, N-methyl-D-aspartate receptor ag-
onists, and other agents. Choosing among agents 
can be daunting for clinicians. Consensus guide-
lines have been developed by an expert panel to 
guide clinicians when there is a variation in prac-
tice and lack of firm evidence in support of either 
of these interventions. In this article, recommen-
dations regarding medications are coherent with 
the consensus panel (23).
The first line of treatment includes morphine 
and hydromorphone, and has clear support from 
data and extensive clinical experience. Recent 
studies continue to support the fact that intra-
thecal morphine provides good analgesia in pa-
tients with chronic refractory pain (24,25). An-
other retrospective study examined the effects of 
hydromorphone after treatment with morphine 
found that nausea and drowsiness decreased. Ini-
tially lower extremity edema resolved but only 
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temporary. Pain scores remained comparable 
after the switch from morphine to hydromor-
phone (26). Table 1 shows recommendations of 
dosing according to consensus guidelines.
The second line of treatment may actually be 
chosen as first line in cases where an individu-
al has prominently neuropathic symptoms. This 
consists of either hydromorphone or morphine 
with the addition of bupivacaine or clonidine. 
There is little data to confirm the safety of these 
mixed agents. Some of the expert panelists have 
concern regarding the hypotensive symptoms as-
sociated with clonidine. There is little evidence to 
support the efficacy of clonidine or bupivacaine 
as single agents.
Third line agents show clinical promise but 
both evidence and clinical experience is extreme-
ly limited. Third line drug combinations are cho-
sen only after failure of first and second line drug 
combination treatments, either due to intolera-
ble side effects or inadequate analgesia. Third line 
drug combinations include adding both bupiva-
caine and clonidine to either morphine or hy-
dromorphone. Some case reports have suggested 
that bupivacaine may be more effective in cancer 
patients with intractable mechanical and visceral 
pain with small boluses in addition to basal rate 
(28). If this is unsatisfactory, another third line 
drug combination should be considered, for ex-
ample, adding bupivacaine and clonidine to an 
alternative opioid, before progressing to fourth 
line agents.
Fourth line agents are not supported by clini-
cal research evidence and experience, even by the 
most experienced pain practitioners. Fourth line 
agents include lipophilic opioid agents such as 
fentanyl and gamma-aminobutyric acid (GABA) 
agonists such as baclofen and midolazam. The 
reasoning behind using lipophilic opioids is that 
there would be less drug diffusion to the rostral 
brain centers. Baclofen is a safe and effective drug 
in the intrathecal space used extensively in the 
United States in the management of spasticity. 
Midazolam is used in preservative free solution 
in Europe, where they have experience with this 
drug in advanced cancer (29). The formulation 
in the United States has preservative, and it is 
not the recommendation of the Expert Consen-
sus panel that it be used without further testing.
There has been advancement in the study of 
medication safety in the intrathecal space in the 
last ten years. A number of medications have 
been proven to be safe. Fentanyl, a potent ani-
linopiperidine analog for example, was evaluated 
in several retrospective studies and demonstrated 
good analgesia and no severe adverse effects (30-
32). Methadone has also been studied in the in-
trathecal space. Three studies, two of which were 
prospective, demonstrated pain reduction and im-
provement in QOL scores, in 38 to 80% (33-35).
A double-blind, randomized, crossover, mul-
ticenter study was performed in 24 patients with 
intrathecal pumps with bupivacaine. For four 
consecutive months, their pumps were refilled 
with either the original opioid or its mixture 
with different concentrations of bupivacaine 
(4, 6, or 8 mg/d). Only one patient experienced 
mild side effects from intrathecal bupivacaine. 
It was found that the addition of bupivacaine to 
the intrathecal opioid failed to produce signifi-
cant improvement in pain control, though indi-
viduals did have improved quality of life (QOL) 
scores (36). Conversely, in a retrospective study 
of a mixed population (cancer and failed back 
syndrome), individuals who failed opioids alone 
had bupivacaine added to the intrathecal solu-
tion. These patients were found to have signifi-
cantly lower pain scores and also demonstrated a 
23% dosage reduction in opioid dosage (37). Fi-
nally, adverse effects such as distal limb numb-
Table 1. Medication dosing with maximum concentration (27)
Medication Dose Concentration Comments
Morphine 15 mg/d Max 30 mg/mL inflammatory masses
Hydromophone 10 mg/d Max 30 mg/mL
Bupivacaine 2-30 mg/d 38 mg/mL elderly – blockade
Clonidine 10-1000 μg/d 2000 μg/mL hypotension, sedation, 
peripheral edema, 
arrhythmia, rebound
Croat Med J 2007;48:22-34
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ness, orthostatic hypotension, and urinary reten-
tion have been reported (36).
Ziconotide is a non-opioid, with several stud-
ies examining its efficacy in the intrathecal space. 
Most recently, a randomized, double-blind, pla-
cebo-controlled study of ziconotide in the intra-
thecal space was completed with 220 patients 
(38). In this study, a very slow titration was used 
to decrease side effect profile. Patients had signif-
icant pain relief when compared to placebo. It 
was found that a slower titration of ziconotide, 
a non-opioid analgesic, to a low maximum dose 
resulted in significant improvement in pain and 
was better tolerated than in two previous con-
trolled trials (39) that used a faster titration to a 
higher mean dose.
Complications and management
Complications from the implantation of an in-
trathecal pump can be categorized into surgical, 
mechanical, pharmacological, and medical (en-
docrine, edema, infections).
Surgical complications
Surgical complications include: bleeding, neu-
rological injury, infection, cerebral spinal leaks, 
shredded catheters, and malpositioned subcuta-
neous pockets.
Bleeding
Intra-operative bleeding can occur from ineffec-
tive local hemostasis during the procedure. It is 
important to identify and correct systemic fac-
tors prior to surgery by reviewing preoperative 
medications for prescribed anticoagulants, herb-
al, and over the counter medications that can in-
crease the risk of bleeding. Patients who are an-
ticoagulated are not candidates for this type of 
procedure until the coagulation returns to nor-
mal. Regional Anesthesia and Pain Medicine 
guidelines for anticoagulant use during intraspi-
nal therapy should be followed to decrease the 
risk of bleeding (40).
Deep intraspinal bleeding in the epidural or 
intrathecal space, while extremely rare, is a much 
more serious problem and is associated with in-
creased neurological morbidity. The use of fluo-
roscopy is essential in avoiding periosteum and 
spinal tumors which can be sources of bleeding 
during surgery. If bleeding persists, intraoperative 
neurosurgical consult for possible laminectomy 
would be necessary. Intraspinal bleeding can oc-
cur without the surgeon being aware of it. Signif-
icant persistent bleeding can lead to epidural he-
matoma, spinal cord compression, and paralysis. 
Post-operatively, it will present first with increas-
ing back pain that rapidly progresses to neurolog-
ical deficits, including motor weakness, sensory 
changes, and sphincter dysfunction. Later signs 
include fever and nuchal rigidity from blood in 
the subarachnoid space. Emergent magnetic res-
onance imaging (MRI) or computed tomogra-
phy (CT) with contrast is warranted, along with 
a neurosurgical consult for possible epidural he-
matoma evacuation.
Superficial post-operative bleeding around 
the wound is another potential complication. 
A seroma or hematoma can appear at the pump 
site, presenting with swelling, pressure, and pain. 
Leakage of sanguinous or serosanguinous fluid 
may or may not be present from the wound it-
self. Often the site will have diffuse bruising. This 
is a self limiting problem that requires monitor-
ing. Abdominal binders are sometimes helpful 
by applying direct pressure over the site to reduce 
the swelling and discomfort.
Catheter complications
Intrathecal pump catheter complications are the 
most common cause of failure in drug delivery 
(Table 2). Intra-abdominal positioning of the intra-
thecal pump may lead to the pump catheter neck to 
prematurely fracture and cause leakage (41).
Neurologic injury
Neurologic injury can result from the actual 
catheter placement, as well as from an inflamma-
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tory response that occurs at the catheter tip and 
is associated with drug delivery.
The implantation of spinal catheters for in-
trathecal drug delivery is done under fluorosco-
py. The catheters are inserted through a spinal 
needle into the spinal canal. Damage to the nerve 
roots or the spinal cord itself during catheter in-
sertion could occur, resulting in pain, sensory 
loss, and/or weakness. The deficits would present 
in the dermatomal distribution of the damaged 
nerve root. Damage to the spinal cord would lead 
to dysesthesias or myelopathies below the level of 
the damaged spinal cord. Also, intraparenchymal 
injury can occur (42,43), as well as cauda equi-
na syndrome with pain, sensory loss, weakness, 
and bowel and bladder dysfunction. The deficits 
would present in multiple dermatomes in a sad-
dle distribution. Neurologic injury can also de-
velop later. One patient developed progressive 
necrotic myelopathy leading to paraplegia, a rare 
form of transverse myelitis (44). It is important 
for the surgeon to obtain pre-operative CT or 
MRI to check for canal stenosis, arachnoiditis, or 
other intraspinal abnormalities that would make 
insertion of the catheter more difficult.
Inflammatory mass
The development of neurologic symptoms can 
also be associated with the formation of an in-
flammatory mass at the tip of the spinal catheter. 
This inflammatory response leads to the devel-
opment of an expanding sterile mass, known as a 
granuloma at the tip of the catheter. The practi-
tioner should suspect the development of a gran-
uloma if the pain presents as a new or increasing 
pain that worsens despite escalating doses of in-
trathecal opioids or if new neurologic symptoms 
arise. An MRI should be obtained to confirm 
the mass around the tip of the catheter. Cath-
eter tip masses are visualized best by using intra-
venous contrast-enhanced T1-weighted images. 
The mass will appear as an enhancing lesion hav-
ing the tip of the drug catheter embedded within 
it. For patients with contraindications to MRI, a 
high resolution CT-myelogram provides an al-
ternative for detecting this type of mass (45). 
Failing to diagnose this condition could lead to 
permanent neurologic injury (46,47).
While the etiology is not clear, it appears 
that the use of high concentrations of opioid, 
morphine specifically, may be the culprit of this 
complication. Studies have shown that granu-
loma formation does not occur in patients re-
ceiving non-opioid intrathecal infusions, such 
as baclofen and therefore does not appear to be 
associated with catheter placement or infusion 
rates (48). Its onset appears to be within sever-
al months of the onset of the utilization of mor-
phine in the intrathecal space. Typically, indi-
viduals present with an increase in pain that 
precedes signs and symptoms of neurologic de-
terioration (49). There is also a suggestion that 
clonidine used in combination with opioids may 
decrease the incidence of this complication. A 
broad consensus exists within the discipline of 
pain management that intrathecal opioids should 
be prescribed and maintained at the lowest effec-
tive dose for as long as possible (46). More specif-
ically, it is recommended that the concentrations 
of the medications be kept as low as possible to 
decrease the incidence of granuloma formation. 
There is a causal relationship between intrathecal 
morphine sulfate infusion and the formation of 
catheter-tip inflammatory masses. The incidence 
of inflammatory masses increased with increas-
ing dosage and concentration. In animal models, 
studies have not yet been able to distinguish be-
Table 2. Catheter complications from three Meditronic spon-
sored clinical studies (http://www.medtronic.com/ )











Distal segment in cerebrospinal fluid 0.1
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tween these variables (50-52). Once identified, 
the treatment and management of this complica-
tion is determined by the clinical condition of the 
patient. A neurosurgical evaluation should be ob-
tained and the risk for neurologic injury assessed. 
If there are no neurologic deficits, then the pump 
medication with preservative free saline infused 
at the minimum pump rate should be replaced. 
Monthly serial MRIs to observe the regression of 
the mass is recommended. Once resolved, restart 
a non-offending opioid and monitor the patient 
closely for reoccurrence by obtaining an MRI ev-
ery three months (53). If neurologic deficits are 
present, then spinal cord decompression, mass 
removal, and catheter removal are indicated. The 
pump itself could remain for future use if anoth-
er catheter placement is determined to be appro-
priate. Consequently, masses identified early that 
do not significantly compress neural structures 
or compromise neurologic function are thought 
to be treated safely and effectively by removing 
the opioid from the pump and monitoring the 
patient until the mass has resolved.
Recent studies in animals by Allen et al (54) 
demonstrated granuloma formation is possible 
and predictably able to be elicited with almost all 
infusions. They infused the maximum concentra-
tion of each intrathecal drug used clinically. They 
demonstrated in dogs, that the agonists mor-
phine, hydromorphone, methadone, and nal-
oxone all could predictably induce granuloma. 
Fentanyl, interestingly, could not. For agonists 
that do produce masses, the concentration, rath-
er than the total dose, appears to be an important 
determinant.
Infection
Preventing infections requires the use of strict 
sterile techniques, antibiotics, and monitoring. 
It is wise to use pre-operative and intra-opera-
tive antibiotics. Some practitioners advocate the 
use of intra-operative antibiotic irrigation as well 
(55). Since most operative infections are caused 
by staphylococcal infections, cephalosporin or 
vancomycin are used by most surgeons. The anti-
microbial drugs of choice for prophylaxis during 
implantation are given in Table 3 (56).
If a patient is a known carrier of methicil-
lin resistant Staphylococcus aureus (MRSA), it is 
wise to obtain a nasal swab pre-op and treat with 
vancomycin if found to be positive. Repeat nasal 
swabs should be done until clear before proceed-
ing with the procedure. Cleansing the skin with 
hibiclens (chlorhexidine gluconate 4% topical 
liquid) prior to surgery may also offer some re-
duction in staphylococcal infections post-opera-
tively.
Wound infections need to be identified early 
and treated aggressively to prevent serious com-
plications. The practitioner should monitor the 
patient for increased pain at the surgical site, ery-
thema, tenderness, swelling, drainage, fever, and 
leukocytosis. Consultants in infectious disease 
should be involved to determine the appropriate 
treatment course whenever infection is suspected.
Not all wound infections require the removal 
of the implanted hardware; superficial infections 
should be cultured and treated with appropriate 
antibiotics. More serious infections involving the 
catheter or pocket will require the removal of all 
the implanted hardware, followed by appropriate 
antibiotic therapy. Failure to remove the catheter 
and pump can lead to ongoing infection and po-
tential progression of the infection. Once the 
material has been removed, the wound should 
be left open and wet to dry, with sterile normal 
saline dressings done until the wound closes on 
its own.
Infections involving the epidural or intra-
thecal space require immediate removal of all 
Table 3. Antimicrobial drugs of choice for prophylaxis during 
implantation of intrathecal pump
Medication Dose Time of drug application
Cefazolin 1-2 g IV 30 min prior to incision
Clindamycin 600 g IV 30 min prior to incision for B-lactam allergy
Vancomycin 1 g IV 30 min prior to incision methicillin resistant 
staph aureus (MRSA) history
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implanted devices and intravenous antibiotics. 
Epidural infections can lead to epidural abscess 
which can compress the thecal sac and cause neu-
rologic injury. If an abscess is suspected, an MRI 
or CT should be obtained urgently. If positive, 
all implanted hardware should be removed, the 
spine decompressed, and appropriate antibiotics 
started.
Intrathecal infections are rare and present 
with fever, nuchal rigidity, changes in level of 
consciousness, leukocytosis, elevated erythrocyte 
sedimentation rate, and C reactive protein. The 
diagnosis is confirmed by positive bacterial CSF 
cultures. Removal of all implanted hardware and 
appropriate antibiotics treatment is necessary. 
Late infectious complications can also occur. 
One case was reported with transverse myelitis 
associated with an Acinetobacter Baumanii in-
trathecal pump catheter-related infection. The 
individual’s clinical course improved with the 
co-administration of intravenous corticosteroids 
and antibiotics (57). Further, there is one retro-
spective study that suggests patients with neu-
ropathic pain syndromes, particularly chronic 
regional pain syndrome had significantly more 
epidural space infections than patients with so-
matic pain (58).
Cerebral spinal fluid leaks
Cerebral spinal fluid leaks may occur in as much 
as 20% of the patients who have an intrathecal 
drug delivery system placed. The epidural space is 
accessed with a 17-gauge Tuohy needle followed 
by the placement of a smaller diameter catheter. 
When the needle is removed, a CSF leak is likely 
to occur. Persistent CSF leaks can lead to a post-
dural puncture headache. In most instances these 
headaches will disappear over time. They can be 
managed conservatively with increased fluids, 
caffeine intake, and bed rest. However, some pa-
tients develop nausea, vomiting, photosensitivity, 
ringing in the ears, and too severe headache. An 
autologous epidural blood patch can be done to 
relieve the symptoms. The procedure should be 
done under fluoroscopy to avoid damaging the 
implanted catheter and strict attention to aseptic 
technique to avoid infection.
Hygroma
In a severe leak a hygroma may develop which 
is an accumulation of CSF subcutaneously near 
the dorsal incision. The complication will usual-
ly resolve spontaneously in 1-2 weeks. Aspiration 
of this fluid should be avoided due to the risk of 
contamination and subsequent infection. A large 
leak that is draining from the incision may re-
quire surgical revision.
Seroma
Formation of seromas is also common around 
the pump pocket. When a pocket is made, fluid 
accumulation at the pocket may develop. This 
can last for 1-2 months and is self-limiting. Ab-
dominal binders are somewhat helpful in reduc-
ing the size and discomfort of the seroma and 
may promote healing. If infection is suspected, 
the fluid should be aspirated and a Gram stain, 
culture, and sensitivity obtained. All seromas will 
contain high levels of white blood cells; therefore 
bacteria must be present to confirm an infection. 
If infection is present, the pump reservoir and 
side port should not be accessed for fear of con-
tamination. An appropriate antibiotic therapy 
should be initiated and hardware removed.
Medications
Medications errors are a common complication 
in intrathecal pump drug delivery. Drug refills 
must be done by trained individuals who are able 
to accurately assess pain, conduct physical exam-
inations, and assess subtle changes in condition. 
It is also important that pain management cen-
ters must be extremely vigilant about their source 
of medications. An incident occurred when 8 of 
13 patients experienced neurologic complica-
tions while receiving morphine in refills of their 
pumps during one 4-week period in a neurosur-
Croat Med J 2007;48:22-34
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gical practice. Three persons underwent laminec-
tomy for sterile abscesses and were left with new 
paralysis or leg weakness. After investigation, 
it was found that several bottles from the com-
pounding pharmacy had contaminants (59).
Endocrine
In one retrospective study, it also has been found 
that patients receiving intrathecal opioids exhib-
ited changes in their neuroendocrine function. 
In 73 patients with non-cancer pain, the major-
ity of patients developed hypogonadotropic hy-
pogonadism. Fifteen percent developed central 
hypocortisolism. Ninety-six per cent of men and 
69% of women who received intrathecal opioids 
reported decreased libido. Hormone replace-
ment ameliorated these effects (60).
Tolerance
Drug tolerance can best be described as the need 
for dose escalation for equivalent effect. There are 
multiple aspects to drug tolerance. It is thought 
that there are psychological or learned aspects to 
drug tolerance. There are also pharmacological or 
physiological aspects to drug tolerance. There ap-
pears to be no drug tolerance to gastrointestinal 
effects, as those are mediated by direct bowel re-
ceptors with less central nervous system control 
(61). There are multiple adaptations in the spine, 
including increased activities of sensory neuro-
peptides (calcitonin gene-related peptide and 
substance P) and their downstream messengers, 
prostaglandins, lipooxygenase metabolites, and 
endocannabinoid (62-64). Evidence is also ac-
cumulating that opioid tolerance is inhibited by 
N-methyl-D-aspartate receptor antagonists. In 
addition, intracellular cascades including those 
involving protein kinase C, can contribute to the 
development of neuroplastic changes that can be 
associated with degenerative neuronal changes in 
the spinal cord (65). There are suggestive parallels 
between these changes and those associated with 
peripheral nerve injury, leading some research-
ers to drawing a mechanistic similarity between 
opioid tolerance and neuropathic pain (66,67). 
Much research has elucidated the mechanisms of 
tolerance in animal studies, but there are difficul-
ties in correlating their results with human sub-
jects. Dose escalation in humans is moderated 
by a number of factors both in the subject and in 
the provider. Besides that, animal studies are un-
equivocal in the demonstration of tolerance via 
multiple mechanisms.
Future outlook
Just like any other technology that comes to re-
place an existing practice, intrathecal pump im-
plantation has its advocates and its detractors. 
One concern is whether the elimination of sys-
temic side-effects justifies a major procedure that 
has its own potential serious complications. In a 
fee-based medical system, there can be a financial 
incentive for the physician for placing intrathe-
cal pumps. Conversely, there is a financial bur-
den for the medical system for such an expen-
sive device to be placed and then supported. A 
Canadian study from 2002 suggested that in pa-
tients who responded to this treatment, intrathe-
cal drug treatment for failed low back syndrome 
is cost-effective in the long term, despite high ini-
tial costs of implantable devices (27).
Since there is no solid outcome evidence that 
supports their use, this article only attempts to 
highlight and update the achievement in the field 
so far and perhaps raise questions in the minds 
of the readers. Especially questions that the pain 
management community and the governing so-
cieties have failed to answer thus far. Random-
ized studies are still scarce. Funding prioritization 
from institutes such as the National Institute of 
Health (NIH) have not matched the need for 
this growing sector of health care. Therefore, ad-
equate evidence is still missing. In fact, due to its 
invasive nature, we believe it needs to be spared 
for patients with advanced malignancies and per-
haps select patients with chronic non-malignant 
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pain where large doses of opioids are needed and 
side-effects limits additional dosing changes.
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